A trial to see if a new vaccine can help treat advanced melanoma

Cancer type:

Eye cancer
Melanoma of the eye
Skin cancer




Phase 1

This trial was looking at a new vaccine called polyMEL to treat melanoma skin cancer or melanoma of the eye (ocular melanoma) that had spread.

More about this trial

It can be difficult to treat advanced melanomaChemotherapy can help control symptoms, but it may not work for everybody.

This trial was looking at a new treatment called polyMEL for melanoma that had spread. PolyMEL is a type of biological therapy called a DNA vaccine Open a glossary item.

Cells of the immune system search for and kill abnormal cells. But they don’t always recognise cancer cells as being abnormal. The polyMEL vaccine works by teaching immune system cells to recognise certain proteins (antigens) made by melanoma cells. This may help the immune system to kill the melanoma cells.

The aims of this trial were to find out

  • The highest dose of polyMEL vaccine that you can safely have
  • What the side effects are
  • What happens to polyMEL inside the body
  • The effect polyMEL has on the immune system
  • How well polyMEL works for advanced melanoma

Summary of results

The researchers found the treatment helped people with ocular melanoma more than people with melanoma skin cancer. The trial recruited 15 people

  • 10 had stage 4 melanoma skin cancer
  • 5 had had stage 4 ocular melanoma that could not be removed with surgery

The first few people taking part had a low dose of polyMEL. As they didn’t have any serious side effects, the next few people had a higher dose. And so on. This is called dose escalation study. All 4 dose levels of polyMEL given in this trial seemed to be safe.

Everybody taking part had PolyMEL injections into a muscle, either in their upper arm or thigh. They had injections every 2 weeks, up to 3 times. They had a CT scan 8 weeks after starting treatment.

  • 2 people left the trial early as they had become more unwell
  • 1 person could not stay in the trial because doctors found their melanoma had spread to their brain

So, the trial team had results for 12 people. The CT scan results showed that melanoma had got worse in all the people taking part who had melanoma skin cancer. But in 3 of the 5 people with ocular melanoma, the cancer stayed the same size. Researchers call this stable disease Open a glossary item.
Tiredness (fatigue) was the most common side effect, but it was not severe.

As they found the treatment to be safe, the researchers suggest that further trials could look at having polyMEL alongside other treatments. It may be particularly useful for people who have ocular melanoma that has spread.

We have based this summary on information from the team who ran the trial. As far as we are aware, the information they sent us has not been reviewed independently (peer reviewed Open a glossary item) or published in a medical journal yet. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor Poulam Patel

Supported by

Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)

If you have questions about the trial please contact our cancer information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:


Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Charlie took part in a trial to try new treatments

A picture of Charlie

“I think it’s really important that people keep signing up to these type of trials to push research forward.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think